Biomedical Catalyst

Funding for innovative businesses and academics that are looking to develop solutions to healthcare challenges in the UK. The programme will seek to support those opportunities which demonstrate the highest scientific and commercial potential, irrespective of medical area.

The programme has an overall budget of £180 million of grant funding available.

Three categories of grant are available. The categories are designed to support the maturation of an idea from concept to commercialisation. This is expected to create a ‘pipeline of projects’ encompassing the early stage exploration of commercial and technical potential through to proving utility in the field (which may involve human clinical trials) and development prior to commercialisation.

The three categories of grant are described below. Applicants may apply for the award category most appropriate for their work without having received a prior award.

Feasibility award

This grant enables the exploration and evaluation of the commercial potential of an early-stage scientific idea, through:

  • review of research evidence and identification of application
  • assessment of business opportunity
  • investigation of intellectual property position
  • experimental studies to validate initial concepts or existing pre-clinical work
  • scoping for further development.

Key features of feasibility award:

  • Projects can last from 3 to 12 months
  • The maximum grant available is £150,000
  • Projects will be funded at 75% of total eligible project costs.

Early-stage award

This grant is to evaluate the technical feasibility of an idea and establish proof of concept in a model system, through:

  • experimental evaluation (lab-scale)
  • initial demonstration using in vitro and in vivo models (not human trials)
  • exploration of potential production mechanisms
  • early-stage prototyping
  • product development planning
  • intellectual property protection

Key features of early-stage award:

  • Projects can last from 1 to 3 years
  • The maximum grant available is £2.4 million
  • The minimum project size is £250,000
  • Projects will be funded at up to 50% of total eligible project costs

Late-stage award

This grant takes a well-developed concept and demonstrates its effectiveness in a relevant environment through:

  • initial human proof-of-concept studies
  • demonstration of clinical utility and effectiveness
  • demonstration of safety and efficacy (including phase I and II clinical trials)
  • development of production mechanisms
  • prototyping
  • market testing
  • intellectual property protection

Key features of late-stage award:

  • Projects can last from 1 to 3 years
  • The maximum grant available is £2.4 million
  • The minimum project size is £250,000
  • Projects will be funded at up to 50% of total eligible project costs.
Apply